Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Clinuvel PharmaceuticalsCLVLF 87 EV-to-EBIT is 4.88 as of Aug. 03, 2026, which is 83% below its 10-year median of 28.05. GuruFocus rates CLVLF with a GF Score™ of 87/100 and a GF Value™ of $11.76 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 387 Biotechnology companies, Clinuvel Pharmaceuticals ranks better than 63.05% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Clinuvel Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2025 was $231.95 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Clinuvel Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $32.29 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clinuvel Pharmaceuticals EV-to-EBIT Related Terms
Clinuvel Pharmaceuticals EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Clinuvel Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinuvel Pharmaceuticals EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Clinuvel Pharmaceuticals's EV-to-EBIT falls into.
Clinuvel Pharmaceuticals's current Enterprise Value is $157.49 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Clinuvel Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $32.29 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clinuvel Pharmaceuticals (CLVLF) has a EV-to-EBIT of 4.88 as of Aug. 03, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Clinuvel Pharmaceuticals and its competitors. This is 83% below median its historical median of 28.05. According to the industry distribution chart, Clinuvel Pharmaceuticals ranks #143 out of 387 companies in the Biotechnology industry, placing it in the top 37%.
Is Clinuvel Pharmaceuticals' EV-to-EBIT too high?
Clinuvel Pharmaceuticals' current EV-to-EBIT of 4.88 is 83% below median its 10-year median of 28.05. The Biotechnology industry median EV-to-EBIT is 12.63. Clinuvel Pharmaceuticals' value of 4.88 is 61.4% below this industry median. Based on the distribution chart, Clinuvel Pharmaceuticals ranks #143 out of 387 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Clinuvel Pharmaceuticals has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Clinuvel Pharmaceuticals' EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Clinuvel Pharmaceuticals ranks #143 out of 387 companies for EV-to-EBIT. This puts Clinuvel Pharmaceuticals in the upper half of its industry. The industry median EV-to-EBIT is 12.63. Clinuvel Pharmaceuticals' value of 4.88 is 61.4% below this benchmark. While the company's 10-year median is 28.05 vs. the industry median of 12.63, Clinuvel Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 12.63, based on 387 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clinuvel Pharmaceuticals's current EV-to-EBIT of 4.88 is 61.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Clinuvel Pharmaceuticals and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 12.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clinuvel Pharmaceuticals's current EV-to-EBIT is 4.88, which is 83% below median its own 10-year median of 28.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinuvel Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals (CLVLF) is currently considered Significantly Undervalued. The stock's GF Value™ is $11.76, compared to a current price of $6.37 — trading 45.8% below its estimated fair value. The current EV-to-EBIT is 4.88, which is 83% below median its 10-year median of 28.05 and 61.4% below the Biotechnology industry median of 12.63. Clinuvel Pharmaceuticals' overall GF Score™ is 87/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Clinuvel Pharmaceuticals (CLVLF), the current EV-to-EBIT is 4.88 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clinuvel Pharmaceuticals (CLVLF) Overvalued in 2026?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals stock appears to be undervalued.
The current stock price of $6.37 is trading 45.8% below its estimated GF Value™ of $11.76.
GuruFocus considers Clinuvel Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for CLVLF:
EV-to-EBIT: 4.88 (83% below median its 10-year median of 28.05)
GF Value™: $11.76 vs. price of $6.37 (45.8% below fair value)
Industry Position: 61.4% below the Biotechnology median (#143 of 387)
No single metric tells the full story. See the CLVLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.
87GF Score
Get the complete analysis for CLVLF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLVLF has been successfully added to your 
